Fujifilm pours $1.2B into US facility in biologics CDMO push
11 Apr 2024
ADC
Fujifilm is dramatically scaling up its biopharmaceutical contract manufacturing capabilities in the US with a $1.2-billion investment to expand its facility in Holly Springs, North Carolina.
The outlay will swell Fujifilm Diosynth Biotechnologies' total planned investment at the site to over $3.2 billion, creating one of the largest cell-culture contract development and manufacturing organisations (CDMOs) in North America, according to the company.
Pointing to growing demand for antibody therapeutics, including monoclonals, bispecifics, and antibody-drug conjugates (ADCs), Fujifilm says the expansion will add eight 20,000L bioreactors for large-scale mammalian cell culture by 2028.
That's in addition to another eight 20,000L bioreactors for bulk drug substance that were part of its initial $2-billion investment in the plant back in 2021.
"This investment is an important step to further accelerate the growth of our biopharmaceutical CDMO business," stated Teiichi Goto, CEO of Fujifilm Corporation.
With the expansion, the company plans to open up 680 new highly-skilled local jobs by 2031 on top of the 725 roles it initially said would be created from the first phase.
According to a report in Nikkei Business Daily, Fujifilm is planning a total $4.5 billion in investments through 2028 in its global biopharmaceutical manufacturing sites, including in Japan and Europe, as it looks to step up competition with leading CDMOs like Lonza, Wuxi Biologics and Samsung Biologics.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.